Can gastric sleeve surgery cause early menopause? It is a question increasingly raised by women considering or recovering from sleeve gastrectomy, and one that deserves a careful, evidence-based answer. Gastric sleeve surgery triggers significant hormonal changes — affecting gut hormones, fat-derived oestrogen, and the hypothalamic-pituitary axis — that can disrupt menstrual cycles, particularly during rapid weight loss. However, the relationship between bariatric surgery and early menopause is complex and nuanced. This article explores what the current evidence shows, how to distinguish temporary hormonal disruption from true ovarian insufficiency, and when to seek medical advice.

How Gastric Sleeve Surgery Affects Hormonal Balance

Gastric sleeve surgery substantially reduces ghrelin levels and alters gut hormones including GLP-1 and PYY, which may interact with the hypothalamic-pituitary-ovarian axis; declining fat stores also reduce peripheral oestrogen production via aromatisation.

Worried about interactions with other medications? Speak to one of our pharmacists →

Gastric sleeve surgery, formally known as sleeve gastrectomy, is a bariatric procedure that removes approximately 75–80% of the stomach, restricting food intake and promoting significant weight loss. Beyond its mechanical effects, the surgery triggers a range of hormonal changes that extend well beyond the digestive system. The gastrointestinal tract is a major endocrine organ, and altering its anatomy has measurable effects on hormone production and regulation.

One of the most significant hormonal shifts involves ghrelin, the so-called 'hunger hormone', which is produced predominantly in the fundus of the stomach — the portion removed during a sleeve gastrectomy. Ghrelin levels fall substantially after surgery, influencing appetite and metabolism. Other gut hormones also change: levels of GLP-1 (glucagon-like peptide-1) and PYY (peptide YY) tend to rise, whilst leptin — a hormone produced by fat tissue — decreases as body fat is lost. These changes may interact with the hypothalamic-pituitary axis, which governs reproductive hormone signalling, though the precise clinical significance of these interactions is not yet fully established.

The hypothalamic-pituitary-ovarian (HPO) axis controls the release of oestrogen and progesterone through a finely tuned feedback loop. Rapid changes in body composition, caloric intake, and circulating hormones — all of which occur after gastric sleeve surgery — may affect this axis, though current evidence does not allow firm conclusions about the degree or duration of any such disruption. Additionally, adipose (fat) tissue is itself a source of oestrogen production via a process called peripheral aromatisation. As fat stores decrease following surgery, oestrogen levels may fluctuate, potentially affecting menstrual regularity and broader hormonal health in women of reproductive age.

Link Between Rapid Weight Loss and Menstrual Changes

Rapid weight loss after sleeve gastrectomy can suppress GnRH signalling, causing temporary irregular periods or amenorrhoea; however, surgery often improves menstrual regularity long-term, particularly in women with PCOS or obesity-related oestrogen excess.

It is well established that significant and rapid weight loss — regardless of its cause — can disrupt the menstrual cycle. After gastric sleeve surgery, many women experience changes to their periods in the months following the procedure. These changes can include:

• Irregular periods or cycles that become unpredictable

• Amenorrhoea (absence of periods) lasting several months

• Changes in cycle length or flow

These disruptions are largely attributed to the body's response to a sudden reduction in caloric intake and rapid fat loss. When energy availability drops sharply, the hypothalamus may reduce its output of gonadotrophin-releasing hormone (GnRH), which in turn suppresses the release of luteinising hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This suppression can temporarily impair ovulation and menstruation — a condition sometimes referred to as functional hypothalamic amenorrhoea.

Important: weight loss after bariatric surgery can increase fertility, even before periods fully regularise. If periods are absent following surgery, a pregnancy test should be one of the first steps in assessment, before any hormonal investigations are undertaken. Women who do not wish to become pregnant should ensure they are using reliable contraception; the Faculty of Sexual and Reproductive Healthcare (FSRH) advises that pregnancy is generally best avoided for at least 12–18 months after bariatric surgery, when nutritional status is most likely to be optimised.

For many women — particularly those who were previously overweight or living with obesity — gastric sleeve surgery can actually improve menstrual regularity over time. Conditions such as polycystic ovary syndrome (PCOS), which is closely linked to insulin resistance and excess weight, often improve following significant weight loss. Oestrogen excess associated with obesity may also normalise. The relationship between gastric sleeve surgery and menstrual health is therefore nuanced and not uniformly negative. The key distinction is between temporary disruption during the active weight-loss phase and any longer-term hormonal consequences.

Early Menopause and Premature Ovarian Insufficiency: Definitions, Causes and UK Guidance

Early menopause is defined as menopause between ages 40–45, while POI occurs before 40 and affects around 1 in 100 UK women under 40; NICE NG23 recommends HRT for both conditions to protect bone and cardiovascular health.

It is important to distinguish between two related but separate conditions:

• Early menopause refers to the permanent cessation of menstruation between the ages of 40 and 45.

• Premature ovarian insufficiency (POI) refers to ovarian failure before the age of 40, and affects approximately 1 in 100 women under 40 in the UK, according to NHS guidance.

These are distinct from the natural menopause, which occurs at an average age of 51 in the UK.

Diagnosis should follow NICE guideline NG23 and ESHRE POI guidance:

• In women over 45, menopause is a clinical diagnosis based on symptoms; routine FSH testing is not recommended.

• In women aged 40–45 with menopausal symptoms, FSH testing may be considered to support the diagnosis.

• For POI (under 40), diagnosis requires at least four months of oligo/amenorrhoea alongside FSH levels in the menopausal range on two separate occasions at least four to six weeks apart.

The causes of early menopause and POI are varied and include:

• Genetic factors (e.g., Turner syndrome, fragile X premutation)

• Autoimmune conditions affecting ovarian tissue

• Medical treatments such as chemotherapy or pelvic radiotherapy

• Surgical removal of the ovaries (bilateral oophorectomy)

• Chromosomal abnormalities

• Idiopathic causes (no identifiable reason, in many cases)

NICE guideline NG23 recommends that women diagnosed with early menopause or POI should be offered hormone replacement therapy (HRT) unless contraindicated, primarily to protect bone density and cardiovascular health, and to manage symptoms. Women with POI are advised to continue HRT until at least the average age of natural menopause (around 51), unless there is a specific contraindication. Women with an intact uterus must take a progestogen alongside oestrogen to protect the endometrium.

Women with POI should also be considered for bone mineral density assessment (DEXA scan) at baseline and at appropriate intervals, given the increased risk of osteoporosis associated with prolonged oestrogen deficiency.

The NHS also recommends psychological support, as a diagnosis of early menopause or POI can have significant emotional and fertility-related implications. Lifestyle factors such as smoking and very low body weight are recognised risk factors for earlier onset of menopause, though these are distinct from the surgical context of bariatric procedures.

What the Evidence Says About Bariatric Surgery and Menopause

Current evidence does not establish that gastric sleeve surgery directly causes early menopause or POI; transient perimenopausal-type symptoms during rapid weight loss reflect hormonal instability rather than confirmed ovarian failure.

The direct question of whether gastric sleeve surgery can cause early menopause is one that current evidence does not definitively answer. There is no established clinical consensus or official guidance from bodies such as NICE, the NHS, or the MHRA stating that gastric sleeve surgery directly causes early menopause or premature ovarian insufficiency.

However, a growing body of research has begun to explore the relationship between bariatric surgery and reproductive hormones. Some observational studies have noted that women undergoing bariatric procedures may experience temporary hormonal fluctuations that resemble perimenopausal symptoms — including hot flushes, night sweats, and mood changes — particularly during the rapid weight-loss phase. These symptoms are thought to reflect transient hormonal instability rather than true ovarian failure. Studies examining FSH and oestradiol levels in this context have not consistently demonstrated findings indicative of true ovarian insufficiency.

Nutritional deficiencies — particularly in vitamin D, zinc, and B vitamins — are common after sleeve gastrectomy, primarily due to reduced food intake and altered gastric physiology rather than significant malabsorption (sleeve gastrectomy is principally a restrictive procedure, in contrast to gastric bypass, which has a greater malabsorptive component). These deficiencies may influence hormonal pathways, though the clinical significance of this in relation to reproductive ageing remains under investigation.

It is also worth noting that obesity itself is associated with altered oestrogen metabolism and may mask or delay the onset of menopause. Weight loss following surgery may therefore reveal an underlying hormonal trajectory that was already in progress. In summary, while gastric sleeve surgery does not appear to directly cause early menopause, it may interact with pre-existing hormonal vulnerabilities in ways that warrant careful monitoring.

Managing Hormonal Symptoms After Gastric Sleeve Surgery

Management begins with distinguishing transient post-surgical disruption from true POI, supported by nutritional screening per BOMSS guidance; confirmed early menopause or POI should be treated with HRT per NICE NG23, with transdermal routes preferred where VTE risk exists.

For women experiencing hormonal symptoms following gastric sleeve surgery, a structured and proactive approach to management is recommended. The first step is accurate assessment — distinguishing between transient post-surgical hormonal disruption, nutritional deficiency-related symptoms, and true early menopause or POI. A pregnancy test should be performed early in the assessment of any post-operative amenorrhoea.

Nutritional optimisation is a cornerstone of post-bariatric hormonal health. In line with guidance from the British Obesity and Metabolic Surgery Society (BOMSS), regular monitoring of the following is recommended after sleeve gastrectomy:

• Full blood count and ferritin — for iron-deficiency anaemia, which is common

• Vitamin B12 and folate — important for neurological and metabolic function

• Vitamin D and calcium — critical for bone health, particularly if oestrogen is low

• Parathyroid hormone (PTH) — to assess calcium and vitamin D status

• Liver function tests and urea and electrolytes (U&Es)

• Zinc, copper, and selenium — as indicated by clinical assessment or centre protocol

Thyroid function and other tests may be added based on clinical indication. All patients following gastric sleeve surgery should remain under the care of a bariatric multidisciplinary team (MDT), which typically includes a dietitian, surgeon, and physician, with long-term follow-up.

If hormonal symptoms are confirmed to reflect early menopause or POI, HRT is the recommended treatment in line with NICE NG23. Women with an intact uterus must take a progestogen alongside oestrogen to protect the endometrium. The choice of HRT route should be individualised in discussion with a GP or gynaecologist. Transdermal HRT (patches or gels) is generally preferred where there is concern about venous thromboembolism (VTE) risk, as it avoids the first-pass hepatic effect associated with oral oestrogen. After sleeve gastrectomy — which is primarily restrictive — oral HRT absorption is not usually significantly impaired, unlike after gastric bypass; however, route choice should always be discussed with a clinician experienced in post-bariatric care.

HRT does not provide contraception. Women who do not wish to become pregnant should use reliable contraception, and the FSRH advises avoiding pregnancy for at least 12–18 months after bariatric surgery.

For women diagnosed with POI or early menopause, a baseline DEXA scan to assess bone mineral density should be considered, with follow-up scanning at appropriate intervals.

If you experience any suspected side effects from HRT or other medicines, these can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

When to Seek Medical Advice From Your GP or Specialist

Women should contact their GP promptly if periods are absent for three or more months post-surgery, or if vasomotor, mood, or nutritional deficiency symptoms are persistent; referral to a gynaecologist or BMS-accredited menopause specialist is appropriate if POI or early menopause is confirmed.

Women who have undergone gastric sleeve surgery and are experiencing symptoms that may suggest hormonal disruption or early menopause should not dismiss these as simply 'part of the process'. Timely medical review is important both for quality of life and for long-term health protection.

Contact your GP promptly if you experience any of the following:

• Absence of periods for three months or more following surgery (if not previously amenorrhoeic)

• Hot flushes, night sweats, or vasomotor symptoms that are persistent or distressing

• Significant mood changes, anxiety, or low mood that feel hormonal in nature

• Vaginal dryness or discomfort

• Symptoms of nutritional deficiency such as fatigue, hair loss, or tingling in the extremities

• Any concerns about fertility, particularly if pregnancy is desired in the future

Your GP will first arrange a pregnancy test if periods are absent, before proceeding to hormonal investigations. Hormone testing (FSH, LH, and oestradiol) will be guided by your age and symptoms, in line with NICE NG23: FSH testing is not routinely recommended in women over 45, may be considered in women aged 40–45 with symptoms, and is used as part of the diagnostic work-up for POI in women under 40. A full nutritional screen aligned with BOMSS guidance should also be arranged.

If results suggest POI or early menopause, referral to a gynaecologist or specialist menopause clinic is appropriate. The British Menopause Society (BMS) maintains a directory of accredited menopause specialists across the UK (thebms.org.uk).

It is also advisable to maintain regular follow-up with your bariatric team beyond the initial post-operative period. Hormonal health is an integral part of long-term bariatric outcomes, and open communication between your surgical team, GP, and any specialist involved in your care will ensure a coordinated and evidence-based approach to your wellbeing.

Frequently Asked Questions